Tyrosyl-2-Aminoisobutyryl-Glutamyl-Glycyl-Threonyl-Phenylalanylthreonyl-Seryl-Aspartate-Tyrosyl-Seryl-Isoleucyl-Tyrosyl-Lysyl([2-[2- Aminoethoxy]Ethoxy]Acetyl-[2-[2-Aminoethoxy]Ethoxy]Acetyl-Gamma-Glutamyl-Eicosanoyl)-Glutamyl-Lysyl-Isoleucyl-Alanyl-Alanyl-Glutamine-Glutamyl-Phenylalanyl-Valyl-Asparagine-Chromyl-Leucyl-Leucyl-Alanyl-Glycyl-Glycyl-Prolyl-Seryl-Seryl-Glycyl-Alanyl-Prolyl-Prolyl-Prolyl-Seryl Amide

• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes Pending
  2025-523486-17-00 Phase III 6 countries Kailera Therapeutics Inc.
• Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight and Diabetes Pending
  2025-523510-87-00 Phase III 6 countries Kailera Therapeutics Inc.
• Efficacy and Safety of KAI-9531 compared with Semaglutide in Participants Living With Obesity Who Do Not Have Diabetes Pending
  2025-523511-11-00 Phase III 2 countries Kailera Therapeutics Inc.

Showing 1–3 of 3 trials